Exploiting the Diphtheria Toxin Internalization Receptor Enhances Delivery of Proteins to Lysosomes for Enzyme Replacement Therapy
Authors
Affiliations
Enzyme replacement therapy, in which a functional copy of an enzyme is injected either systemically or directly into the brain of affected individuals, has proven to be an effective strategy for treating certain lysosomal storage diseases. The inefficient uptake of recombinant enzymes via the mannose-6-phosphate receptor, however, prohibits the broad utility of replacement therapy. Here, to improve the efficiency and efficacy of lysosomal enzyme uptake, we exploited the strategy used by diphtheria toxin to enter into the endolysosomal network of cells by creating a chimera between the receptor-binding fragment of diphtheria toxin and the lysosomal hydrolase TPP1. We show that chimeric TPP1 binds with high affinity to target cells and is efficiently delivered into lysosomes. Further, we show superior uptake of chimeric TPP1 over TPP1 alone in brain tissue following intracerebroventricular injection in mice lacking TPP1, demonstrating the potential of this strategy for enhancing lysosomal storage disease therapy.
Discovery of mono-ADP ribosylating toxins with high structural homology to Pseudomonas exotoxin A.
Masuyer G, Taverner A, MacKay J, Lima Marques A, Wang Y, Hunter T Commun Biol. 2025; 8(1):413.
PMID: 40069285 PMC: 11897225. DOI: 10.1038/s42003-025-07845-y.
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics.
Ou L, Setegne M, Elliot J, Shen F, Dassama L Chem Rev. 2025; 125(4):2120-2183.
PMID: 39818743 PMC: 11870016. DOI: 10.1021/acs.chemrev.4c00595.
Rosenkranz A, Slastnikova T Pharmaceutics. 2023; 15(3).
PMID: 36986848 PMC: 10055131. DOI: 10.3390/pharmaceutics15030987.